Friday, 29 March 2024


AstraZeneca sells European rights for heart failure treatment for $210M

24 July 2018 | News

Cheplapharm would pay AstraZeneca $200m on completion of the agreement, expected to be finalised in the third quarter of 2018, plus a time-bound payment of $10m and sales-contingent milestones.

Singapore -  AstraZeneca has agreed to sell the European commercial rights to hypertension and heart failure meds Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil/hydrochlorothiazide) to Cheplapharm Arzneimittel GmbH.

AZN will continue to manufacture and supply the products under a supply agreement and will continue to commercialize both in all markets where it retains rights.

Under the terms of the agreement, AZN will receive $200M, a time-bound payment of $10M and sales-related milestones. The deal should close this quarter.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account